Pharmacotherapy of obesity

Por Wilding, John P. H.
Publicado em 2008

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus

Por Budoff, Matthew J., Wilding, John P. H.
Publicado no Int J Clin Pract (2017)

1,25-dihydroxyvitamin D(3) Protects against Macrophage-Induced Activation of NFκB and MAPK Signalling and Chemokine Release in Human Adipocytes

Por Ding, Cherlyn, Wilding, John P. H., Bing, Chen
Publicado em 2013

Anti-obesity drugs: past, present and future

Por Rodgers, R. John, Tschöp, Matthias H., Wilding, John P. H.
Publicado em 2012

The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats

Por Pickavance, Lucy C, Brand, Christian L, Wassermann, Karsten, Wilding, John P H
Publicado em 2005

Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic F...

Por Pickavance, Lucy C, Widdowson, Peter S, Foster, John R, Williams, Gareth, Wilding, John P H
Publicado em 2003

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

Por Wilding, John P.H., Norwood, Paul, T'joen, Caroline, Bastien, Arnaud, List, James F., Fiedorek, Fred T.
Publicado em 2009

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Por Ahrén, Bo, Atkin, Stephen L., Charpentier, Guillaume, Warren, Mark L., Wilding, John P. H., Birch, Sune, Holst, Anders Gaarsdal, Leiter, Lawrence A.
Publicado no Diabetes Obes Metab (2018)

Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation

Por O’Neill, Elaine D., Wilding, John P. H., Kahn, C. Ronald, Van Remmen, Holly, McArdle, Anne, Jackson, Malcolm J., Close, Graeme L.
Publicado em 2010

Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes

Por Cefalu, William T., Stenlöf, Kaj, Leiter, Lawrence A., Wilding, John P. H., Blonde, Lawrence, Polidori, David, Xie, John, Sullivan, Daniel, Usiskin, Keith, Canovatchel, William, Meininger, Gary
Publicado no Diabetologia (2015)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

Por O'Neil, Patrick M., Aroda, Vanita R., Astrup, Arne, Kushner, Robert, Lau, David C. W., Wadden, Thomas A., Brett, Jason, Cancino, Ana‐Paula, Wilding, John P. H.
Publicado no Diabetes Obes Metab (2017)

Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose

Por Kos, Katrina, Wong, Steve, Tan, Bee, Gummesson, Anders, Jernas, Margareta, Franck, Niclas, Kerrigan, David, Nystrom, Fredrik H., Carlsson, Lena M.S., Randeva, Harpal S., Pinkney, Jonathan H., Wilding, John P.H.
Publicado em 2009

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)—study...

Por Rajeev, Surya Panicker, Sprung, Victoria S, Roberts, Carl, Harrold, Jo A, Halford, Jason C G, Stancak, Andrej, Boyland, Emma J, Kemp, Graham J, Cuthbertson, Daniel J, Wilding, John P H
Publicado no BMJ Open (2017)

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

Por Skyler, Jay S., Bakris, George L., Bonifacio, Ezio, Darsow, Tamara, Eckel, Robert H., Groop, Leif, Groop, Per-Henrik, Handelsman, Yehuda, Insel, Richard A., Mathieu, Chantal, McElvaine, Allison T., Palmer, Jerry P., Pugliese, Alberto, Schatz, Desmond A., Sosenko, Jay M., Wilding, John P.H., Ratner, Robert E.
Publicado no Diabetes (2017)